亚太地区炎症性肠病的生物制剂：我们用得起吗，不用得起吗？ - Suppr

Suppr

超能文献

Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?

作者信息

Gearry Richard B, Irving Peter M

出版信息

J Gastroenterol Hepatol. 2009 Jul;24(7):1160-2. doi: 10.1111/j.1440-1746.2009.05896.x.

DOI:10.1111/j.1440-1746.2009.05896.x

PMID:19682189

Abstract

摘要

相似文献

Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?

J Gastroenterol Hepatol. 2009 Jul;24(7):1160-2. doi: 10.1111/j.1440-1746.2009.05896.x.

Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.

J Gastroenterol Hepatol. 2009 Jul;24(7):1252-7. doi: 10.1111/j.1440-1746.2009.05786.x. Epub 2009 Feb 12.

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24.

Is keeping the colon the ultimate marker of success in ulcerative colitis?

Gastroenterology. 2009 Oct;137(4):1204-6. doi: 10.1053/j.gastro.2009.08.024. Epub 2009 Aug 28.

Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.

Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):599-609. doi: 10.1586/14737167.2014.957680.

A review of infliximab use in ulcerative colitis.

Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014.

[Biological therapy in children with inflammatory bowel syndrome (clinical cases)].

Eksp Klin Gastroenterol. 2014(1):110-2.

The cost-effectiveness of infliximab in Crohn's disease.

Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):589-98. doi: 10.1586/14737167.2014.950235. Epub 2014 Aug 20.

Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:45-52. doi: 10.1586/17474124.2015.1091308.

Need for infliximab dose intensification in Crohn's disease and ulcerative colitis.

World J Gastroenterol. 2014 Jul 21;20(27):9170-7. doi: 10.3748/wjg.v20.i27.9170.

引用本文的文献

Optimization of conventional therapy in patients with IBD.

Nat Rev Gastroenterol Hepatol. 2011 Oct 4;8(11):646-56. doi: 10.1038/nrgastro.2011.172.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?

J Gastroenterol Hepatol. 2009 Jul;24(7):1160-2. doi: 10.1111/j.1440-1746.2009.05896.x.

Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.

J Gastroenterol Hepatol. 2009 Jul;24(7):1252-7. doi: 10.1111/j.1440-1746.2009.05786.x. Epub 2009 Feb 12.

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24.

Is keeping the colon the ultimate marker of success in ulcerative colitis?

Gastroenterology. 2009 Oct;137(4):1204-6. doi: 10.1053/j.gastro.2009.08.024. Epub 2009 Aug 28.

Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease.

Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):599-609. doi: 10.1586/14737167.2014.957680.

A review of infliximab use in ulcerative colitis.

Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014.

[Biological therapy in children with inflammatory bowel syndrome (clinical cases)].

Eksp Klin Gastroenterol. 2014(1):110-2.

The cost-effectiveness of infliximab in Crohn's disease.

Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):589-98. doi: 10.1586/14737167.2014.950235. Epub 2014 Aug 20.

Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:45-52. doi: 10.1586/17474124.2015.1091308.

Need for infliximab dose intensification in Crohn's disease and ulcerative colitis.

World J Gastroenterol. 2014 Jul 21;20(27):9170-7. doi: 10.3748/wjg.v20.i27.9170.

引用本文的文献

Optimization of conventional therapy in patients with IBD.

Nat Rev Gastroenterol Hepatol. 2011 Oct 4;8(11):646-56. doi: 10.1038/nrgastro.2011.172.